Main results
We included 5 randomised trials with 662 participants out of 93 publications identified through the literature searches. The number of deaths was 47 in the wait-and-see group (334 patients) compared to 26 in the prophylactic cholecystectomy group (328 patients) for a 78% increased risk of mortality (RR 1.78, 95% CI 1.15 to 2.75, P = 0.010). The survival benefit of prophylactic cholecystectomy was independent of trial design, inclusion of high risk patients or inclusion of any one of the five trials. Patients in the wait-and-see group had higher rates of recurrent biliary pain (RR 14.56, 95% CI 4.95 to 42.78, P < 00001), jaundice or cholangitis (RR 2.53, 95% CI 1.09 to 5.87, P = 0.03), and of repeat ERCP or other forms of cholangiography (RR 2.36, 95% CI 1.29 to 4.32, P = 0.005). Cholecystectomy was eventually performed in 35% (115 patients) of the wait-and-see group.
Authors' conclusions
Prophylactic cholecystectomy should be offered to patients whose gallbladders remain in-situ after endoscopic sphincterotomy and common bile duct clearance.
P L A I N L A N G U A G E S U M M A R Y

Prophylactic cholecystectomy should be offered to patients whose gallbladders remain in-situ after endoscopic sphincterotomy and common bile duct clearance
Surgical removal of the gallbladder is done routinely. Stones in the common bile duct usually come from the gallbladder and can be harmful. The usual treatment for gallstones that are in the common bile duct is endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy. ERCP is an endoscopic procedure to remove stones from the common bile duct. More stones may enter the common bile duct from the gallbladder but it is not clear if the gallbladder should be removed preventively (prophylactic cholecystectomy) or if a wait-and-see policy (cholecystectomy deferral) would be better. We included 5 randomised trials with 662 participants out of 93 publications identified through the literature searches. The number of deaths was 47 in the wait-and-see group (334 patients) compared with 26 in the prophylactic cholecystectomy group (328 patients). This review of randomised clinical trials suggests that early removal of the gallbladder decreases the risk of death or of complications from gallstones. The number of patients (662) reviewed in this report prevents some of the subgroup analyses from being conclusive. Further clinical trials, particularly of highrisk patients, would solve this problem.
B A C K G R O U N D
Prior to the development of endoscopic retrograde cholangiopancreatography (ERCP) the treatment of choledocholithiasis-related illness was open cholecystectomy and common bile duct exploration if operative cholangiography confirmed the presence of residual stones in the bile duct. ERCP permits removal of biliary stones without open operation. The importance of its role in the management of choledocholithiasis increased with the development of the laparoscopic approach to cholecystectomy, which initially limited surgical access for common duct exploration (NIH 1992) . Patients with suspected choledocholithiasis were advised to undergo ERCP and endoscopic biliary sphincterotomy before laparoscopic cholecystectomy was considered (Roy 1993; NIH 2002) . The role of ductal pressure in biliary symptoms suggests that some patients may be managed by sphincterotomy alone because it reduces pressure in the biliary tree. Deferral of cholecystectomy after endoscopic sphincterotomy for choledocholithiasis in high-risk patients was first reported almost twenty-five years ago (Escourrou 1984) . Only 13% of 224 patients followed for three years required cholecystectomy. Currently, deferral of cholecystectomy (also known as wait-and-see) is advised in high-risk patients whose choledocholithiasis has been cleared by ERCP (NIH 1992) .
In contrast, retrospective reviews found a higher mortality rate in patients who deferred cholecystectomy after endoscopic sphincterotomy compared to patients who had their gallbladders removed electively (Archibald 2007) . Only randomised clinical trials could have determined if prophylactic cholecystectomy reduced the risk of death. A recent randomised clinical trial of prophylactic cholecystectomy versus wait-and-see in fit patients found a higher incidence of biliary symptoms in the wait-and-see group, of whom 22 (36%) had cholecystectomy performed in the first 20 months after sphincterotomy (Boerma 2002) . No differences were seen in patient survival or in quality of life, but the trial was underpowered for such determinations. An accompanying editorial advised fit patients to undergo prophylactic cholecystectomy following clearance of stones from the bile duct (Cuschieri 2002) . This editorial also suggested that the technique for laparoscopic common bile duct exploration had advanced and that it was now the preferred method over ERCP to clear ductal stones because prophylactic cholecystectomy could be performed at the same operation. However, this view is not universally accepted (Barkun 2005) .
A systematic review of randomised clinical trials is required to determine the benefits and harms of cholecystectomy deferral after endoscopic sphincterotomy versus prophylactic cholecystectomy after either ERCP or common bile duct exploration.
O B J E C T I V E S
To evaluate the beneficial and harmful effects of cholecystectomy deferral (wait-and-see) versus elective (prophylactic) cholecystectomy in patients who have had an endoscopic biliary sphincterotomy.
M E T H O D S Criteria for considering studies for this review
Types of studies
Randomised trials were included irrespective of blinding, language, or publication status (ie, unpublished trials, abstracts, or full paper articles).
Types of participants
Patients with gallbladders left in-situ after endoscopic sphincterotomy.
Types of interventions
Expectant management (cholecystectomy deferral) versus prophylactic (elective) cholecystectomy. Randomised clinical trials that compared endoscopic sphincterotomy followed by expectant management of the gallbladder with either endoscopic sphincterotomy followed by prophylactic cholecystectomy or with common bile duct exploration and prophylactic cholecystectomy were included. Collateral interventions were permitted if applied equally in both arms of the trial.
Types of outcome measures
Primary outcome measures (1) Mortality. Secondary outcome measures (2) Incidence of: biliary pain; recurrent jaundice; pancreatitis; non-biliary abdominal pain; major adverse events; minor adverse events; other morbidities. (8) Adverse events. They were classified as major if they were considered to threaten life, organ or limb function or to substantially prolong hospital stay. Examples of major adverse events include bile duct transection, myocardial infarction, pulmonary embolism and renal failure. Other adverse events were considered to be minor adverse events. Examples of minor adverse events include cystic duct bile leak, respiratory atelectasis and wound infections ( ICH-GCP 1997).
Search methods for identification of studies
We performed electronic searches using the search strategies presented in Appendix 1. We manually went through the results obtained through the searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Controlled Trials Register (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded. The period of time the separate searches cover is also given in Table 1 . Abstracts of Digestive Disease Week were searched for meetings from 1996 to 2006. We also scanned bibliographies in relevant review articles and wrote to authors of included trials. Two of us (V McAlister, E Davenport) evaluated whether these studies fulfil the inclusion criteria.
Data collection and analysis
Data extraction
Two reviewers (V. McAlister and E. Davenport) independently extracted data using standardised extraction forms. Disagreements were resolved by discussion arbitrated by E. Renuof.
From each trial, we tried to extract the following characteristics:
• Patients (inclusions and exclusion criteria, mean age, sex, indication for endoscopic sphincterotomy);
• Interventions (prophylactic cholecystectomy or expectant management);
• Trials (setting, methodological quality, publication status, duration of follow-up, and all outcomes).
Methodological quality
Randomisation and follow-up was extracted as measures of methodological quality using the definitions listed below ( Kjaergard 2001).
Generation of the allocation sequence
To determine if the procedure used to create a random sequence ensured that each patient has a known, unpredictable, and usually equal chance of being assigned to intervention groups, the allocation sequence generation was classified as:
• adequate (if the allocation sequence was generated by a computer or random number table),
• unclear (if the trial was described as randomised, but the method used for the allocation sequence generation was not described), or
• inadequate (if a system involving dates, names, or admittance numbers were used).
Allocation concealment
The procedure used to conceal the allocation sequence from the investigators who assign patients to the intervention groups was assessed. The allocation concealment was classified as:
• adequate (if the allocation of patients involved a central independent unit, sealed envelopes, on-site locked computer, or identically appearing numbered drug bottles or containers prepared by an independent pharmacist),
• unclear (if the trial was described as randomised, but the method used to conceal the allocation was not described), or
• inadequate (if the trial was quasi-randomised).
Blinding
Considering the nature of the intervention, we did not expect that any of the eligible trials would be double blind. Double blinding was, therefore, not be included in our assessment of methodological quality. However, we assessed which trials used blinded outcome assessment.
Follow-up
We extracted the number and reasons for all losses to follow-up to assess the risk of attrition bias.
Statistical analyses
The analyses was performed in RevMan Analysis 1.0 (RevMan 2003) . The number of events and number of patients in all intervention arms was used to calculate relative risks (RR) with 95% confidence intervals (CI). Data were combined in fixed-effect meta-analyses. Random-effects meta-analyses was performed as sensitivity analyses, but was only reported if the results regarding significance differed from the fixed-effect models. Intentionto-treat analyses including all patients irrespective of compliance or follow-up was performed. Carry forward of the last observed response was used for patients with missing data. For the primary outcome measure, evidence of publication bias and other biases was evaluated in regression analyses of funnel plot asymmetry. Sources of heterogeneity was evaluated through sensitivity, subgroup, and meta-regression analyses. The analyses included the extracted patient, intervention, and trial characteristics listed above as explanatory variables. V. McAlister and E. Renouf entered the data and performed all meta-analyses in RevMan. The impact of open versus laparoscopic cholecystectomy was assessed by sensitivity analysis. Sensitivity analysis was also used to assess the impact of trial design: ERCP alone versus prophylactic cholecystectomy after ERCP or ERCP alone versus prophylactic cholecystectomy after common bile duct exploration.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. Searches performed on April 18, 2007 resulted in 330 hits which yielded 93 reports when duplicates were removed. After initial review, seven randomised trials were identified of which two were excluded on further examination because the gallbladder was not left in-situ in the patients (Neoptolemos 1987; Kapoor 1996) . In three of the included trials a wait-and-see policy for the gallbladder after endoscopic sphincterotomy was compared with open cholecystectomy and removal of the common bile duct stones by exploration (Hammarstrom 1995; Targarona 1996; Suc 1998) . In the remaining two trials, a wait-and-see approach regarding the gallbladder after sphincterotomy was compared with prophylactic laparoscopic cholecystectomy after sphincterotomy (Boerma 2002; Lau 2006) . The trials, which were conducted in five countries, involved multiple centres in two (Suc 1998; Boerma 2002) and were single-centred in the remaining three (Hammarstrom 1995; Targarona 1996; Lau 2006) . The five trials included 662 adult patients of whom 334 were allocated to the wait-and-see group and 328 were allocated to the prophylactic cholecystectomy group. Three trials included patients in all American Society of Anaestesiology (ASA) classes (Hammarstrom 1995; Targarona 1996; Suc 1998) and two trials excluded high risk patients with ASA class IV and V physiological scores (Boerma 2002; Lau 2006) .
Risk of bias in included studies
Allocation concealment was adequate in four trials (Targarona 1996; Suc 1998; Boerma 2002 ; Lau 2006) but was not described in one (Hammarstrom 1995) . None of the trials was blinded. In one trial, eight patients were excluded because they did not have gallbladders-in-situ at the time of randomisation; five in the waitand-see group (Suc 1998) and three were in the surgical group. In two trials, a small number of the patients randomised to the prophylactic cholecystectomy group did not actually have a cholecystectomy (Hammarstrom 1995; Boerma 2002) . A follow-up protocol was described in four trials (Hammarstrom 1995; Targarona 1996; Boerma 2002; Lau 2006) . The patients were seen in routine clinics and third party observers were not used. The trial duration was disclosed in each trial, but the actual observation period was given in only three (Hammarstrom 1995; Boerma 2002; Lau 2006) .
Effects of interventions
Primary outcome
All five trials, including 662 patients, reported mortality ( Hammarstrom 1995; Targarona 1996; Suc 1998; Boerma 2002; Lau 2006) . Forty seven patients (14.1%) died in the wait-and-see group and 26 patients (7.9%) died in the prophylactic cholecystectomy group (Analysis 1.1: RR 1.78, 95% CI 1.15 to 2.75, P = 0.010). There was no heterogeneity between the trials (i 2 = 0).
Secondary outcomes
All trials reported all of the secondary outcome measures with the exception of quality-of-life score, which was reported by one trial only (Boerma 2002). Biliary type pain or cholecystitis occurred in 16% of patients who deferred cholecystectomy and this risk was eliminated by prophylactic cholecystectomy (Analysis 1.2: RR 14.56, 95% CI 4.95 to 42.78, P < 00001). Only four patients (three in the wait-and-see group and one in the prophylactic cholecystectomy group) developed pancreatitis (Analysis 1.3: RR 2.11, 95% CI 0.39 to 11.43, P = 0.39). Recurrent jaundice or cholangitis was significantly more common in patients who deferred cholecystectomy (Analysis 1.4: RR 2.53, 95% CI 1.09 to 5.87, P = 0.03). Less adverse events were recorded in patients who deferred cholecystectomy (major adverse events: Analysis 1.5: RR 0.59, 95% CI 0.34 to 1.01, P = 0.06 and minor adverse events: Analysis 1.6: RR 0.49, 95% CI 0.22 to 0.89, P = 0.03). More patients required subsequent ERCP or other forms of cholangiography if cholecystectomy was deferred (Analysis 1.7: RR 2.36, 95% CI 1.29 to 4.32, P = 0.005). Eight patient randomised to the prophylactic cholecystectomy group did not have a cholecystectomy. Cholecystectomy was eventually performed in 35% (115 patients) of the wait-and-see group (Table 1) . There was no difference in the rate of difficult cholecystectomy between the groups (Analysis 1.8: RR 0.68, 95% CI 0.39 to 1.17, P = 0.16). There were no reports of major or minor bile duct complications following cholecystectomy. Only one trial reported hospital re-admission rates ( Targarona 1996) and only one other collected data regarding the quality of life (Boerma 2002). Similar reductions in mortality rates were seen in each of the subgroups, but combination was required to be statistically significant (Analysis 2.1; Analysis 3.1). Recurrent biliary pain was seen only in the patients who deferred cholecystectomy in all subgroups ( Analysis 2.2; Analysis 3.2). Recurrent jaundice and cholangitis occurred more often in the wait-and-see patients in both subgroups (Analysis 2.4; Analysis 3.4). Additional cholangiography was required more often in the wait-and-see group in trials comparing it to prophylactic cholecystectomy after endoscopic sphincterotomy (Analysis 2.7) and in trials that excluded ASA IV or V patients ( Analysis 3.7), but no difference was present when wait-and-see was compared to open cholecystectomy and common bile duct exploration (Analysis 2.7), or in trials that included high-risk patients (Analysis 3.7). Major adverse events were less common (not statistically significant) in the wait-and-see patients of all subgroups (Analysis 2.5; Analysis 3.5). Minor adverse events were reduced in wait-and-see patients of the trials compared to open cholecystectomy and common bile duct exploration (Analysis 2.6) and in trials that included ASA IV or V patients (Analysis 3.6) but not in trials compared to cholecystectomy after sphincterotomy (Analysis 2.6) nor in trials that excluded high risk patients. The eventual cholecystectomy rate was 44.8% (81 patients) and 23% (34 patients) in the wait-and-see group from the open surgery era and the laparoscopic surgery era respectively (Table 1 ), but no difference in the incidence of difficult cholecystectomy was seen between the eventual and prophylactic cholecystectomies in either era (Analysis 2.8) nor between trials that included or excluded high risk patients (Analysis 3.8).
Sensitivity analyses
The influence of each trial on outcome was tested by excluding each trial in rotation and performing pooled analyses of the remaining four trials. The benefit of prophylactic cholecystectomy remained substantial despite removal of each of the trials, one at a time, from the analysis. The relative risk of death is given after the title of each trial which was excluded in the following sensitivity analyses: Boerma 
D I S C U S S I O N
The main conclusions of our review are that the wait-and-see procedure versus removal of the gallbladder leads to more deaths, more patients with biliary pain and cholangitis, more patients with recurrent jaundice and cholangitis, and more additional cholangiographies, but saves cholecystectomies and adverse events. The major limitations of our review are the relatively few trials, the few patients, and the low number of outcomes as well as methodological weaknesses of the trials.
One of the included trials demonstrated a statistically significant increase in mortality in patients deferring cholecystectomy after endoscopic sphincterotomy and clearance of the bile duct ( Hammarstrom 1995) . This trial had a small sample size and its finding might be considered a matter of chance. Subsequent studies were not sufficiently powered to show differences in survival and therefore could not confirm the finding. A surprisingly large proportion of patients have been reported to adopt a wait-and-see policy after sphincterotomy, indicating that neither physicians nor patients have been convinced by the trials individually (Archibald 2007) . This meta-analysis confirms the finding that prophylactic cholecystectomy after endoscopic sphincterotomy reduces mortality. This reduction in mortality was seen particularly in trials that included all patients, even those in the higher risk ASA classes. This finding was evident even though most of the high-risk pa-tients were in trials that compared a wait-and-see policy to open surgery. Cholecystectomy deferral has been advised for high risk patients, but this meta-analysis suggests that the benefit of prophylactic cholecystectomy may accrue particularly to that group of patients.
Technological developments have defined eras in the management of cholelithiasis. The development of ERCP in the late 1980s and of laparoscopy in the 1990s changed the management of gallbladder and common bile duct stones. Randomised clinical trials of a wait-and-see policy were designed to use as a control the technology of their era for bile duct clearance and cholecystectomy. Subgroup analysis showed the superiority of prophylactic cholecystectomy to occur regardless of study design. Superiority of prophylactic cholecystectomy was present even in patients who had open surgery. The laparoscopic approach reduces the morbidity of cholecystectomy and has extended use of the procedure into groups of patients previously thought too frail for open surgery ( Barkun 2005) . It is reasonable to consider prophylactic cholecystectomy for patients in all risk categories after endoscopic sphincterotomy. However, no trial of prophylactic cholecystectomy has yet been carried out in patients initially considered high-risk for surgery.
Laparoscopic common bile duct exploration may alter the options available to deal with choledocholithiasis once again (Cuschieri 2002) . Avoiding the risk of pancreatitis that is inherent with endoscopic sphincterotomy is an attractive element of common bile duct exploration. Of the patients who underwent common bile duct clearance followed by prophylactic cholecystectomy in this review, 7.1% died in the earlier era where choledocholithiasis was dealt with by open common bile duct exploration, whereas 9.2% died in the later endoscopic / laparoscopic era. More trials will be required as new technological solutions, such as robot-assisted common bile duct exploration with its capacity for articulated dissection, are deployed. This meta-analysis demonstrates the importance of designing such trials with appropriate power.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Prophylactic cholecystectomy should be offered to all patients considered fit for surgery, in whom choledocholithiasis has been cleared by ERCP and endoscopic sphincterotomy.
Implications for research
Prophylactic cholecystectomy following clearance of choledocholithiasis should be studied by randomised clinical trial in patients considered high-risk for surgery.
Future trials should be reported following the recommendations of the CONSORT statement (www.consort-statement.org).
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R E F E R E N C E S
References to studies included in this review
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Unclear B -Unclear
Lau 2006
Methods Generation of the allocation sequence: adequate. Randomly assigned using computer-generated random list. (1) immediate, procedure-related: mortality and morbidity, severe complications, minor complications, pre-procedure and post-procedure hospital length of stay.
(2) during long-term follow-up: biliary complications, readmission for biliary complications, cholecystectomy, ERCP, late morbidity.
Notes
Early follow-up defined as follow-up to hospital discharge. Late follow-up protocol included a visit at 30 days or so after discharge and then every three months for first year and every six months thereafter for the length of the study.
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Yes A -Adequate Test for overall effect: Z = 2.37 (P = 0.018) Test for overall effect: Z = 2.37 (P = 0.018) 
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